Literature DB >> 26371709

Investigation of the Annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion.

Charalambos Demetriou1, Sayeda Abu-Amero2, Shawnelle White3, Emma Peskett2, Arseni Markoff4, Philip Stanier2, Gudrun E Moore2, Lesley Regan3.   

Abstract

Annexin A5 is a placental anti-coagulant protein that contains four nucleotide substitutions (M2 haplotype) in its promoter. This haplotype is a risk factor for recurrent spontaneous abortion (RSA). The influence of the M2 haplotype in the gestational timing of spontaneous abortions, paternal risk and relationships with known risk factors were investigated. European couples (n = 500) who had experienced three or more consecutive spontaneous abortions, and two fertile control groups, were selected for this study. The allele frequency of M2 was significantly higher among patients who had experienced early RSA than among controls (P = 0.002). No difference was found between controls and patients who had undergone late spontaneous abortions. No difference was found between patients who had experienced RSA who had a live birth or no live births, or between patients who were positive or negative for known risk factors. Male and female partners in each group had similar allele frequencies of M2. The M2 haplotype is a risk factor for early spontaneous abortions, before the 12th week of gestation, and confers about the same relative risk to carriers of both sexes. Having one or more M2 allele(s) in combination with other risk factors further increases the RSA risk.
Copyright © 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ANXA5; M2 haplotype; annexin A5; recurrent miscarriage; recurrent spontaneous abortion; risk factor

Mesh:

Substances:

Year:  2015        PMID: 26371709     DOI: 10.1016/j.rbmo.2015.07.004

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

1.  Assessment of M2/ANXA5 haplotype as a risk factor in couples with placenta-mediated pregnancy complications.

Authors:  Nina Rogenhofer; Lara R M Nienaber; Lea C Amshoff; Nadia Bogdanova; David Petroff; Peter Wieacker; Christian J Thaler; Arseni Markoff
Journal:  J Assist Reprod Genet       Date:  2017-09-13       Impact factor: 3.412

2.  The relevance of ANXA5 genetic variants on male fertility.

Authors:  Heloisa Lopes Lavorato; Arseni Markoff; Valeria Altholz; Nadja Bogdanova; Peter Wieacker; Sabine Kliesch; Stefan Schlatt
Journal:  J Assist Reprod Genet       Date:  2019-06-13       Impact factor: 3.412

3.  Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications.

Authors:  Federico Aranda; Sebastián Udry; Silvia Perés Wingeyer; Lea Christina Amshoff; Nadja Bogdanova; Peter Wieacker; José Omar Latino; Arseni Markoff; Gabriela de Larrañaga
Journal:  J Assist Reprod Genet       Date:  2018-03-01       Impact factor: 3.412

4.  Genetic analysis of the M2/ANXA5 haplotype as recurrent pregnancy loss predisposition in the Malay population.

Authors:  Kai-Cheen Ang; Sushilnathan Kathirgamanathan; Ewe Seng Ch'ng; Yan-Yeow Lee; Anna-Liza Roslani; Bavanandan Naidu; Krishna Kumar; Ridzuan Abdullah; Siti-Nadiah Abdul Kadir; Narazah Mohd Yusoff; Wan Zaidah Abdullah; Nadja Bogdanova; Peter Wieacker; Arseni Markoff; Thean-Hock Tang
Journal:  J Assist Reprod Genet       Date:  2017-01-20       Impact factor: 3.412

Review 5.  Thrombophilia and Pregnancy Complications.

Authors:  Louise E Simcox; Laura Ormesher; Clare Tower; Ian A Greer
Journal:  Int J Mol Sci       Date:  2015-11-30       Impact factor: 5.923

6.  Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy Outcome.

Authors:  Simon Fishel; Deborah Baker; Janine Elson; Maha Ragunath; Glenn Atkinson; Adel Shaker; Ahmed Omar; Rahnuma Kazem; Ashley Beccles; Ian A Greer
Journal:  EBioMedicine       Date:  2016-07-18       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.